AUPH

Aurinia Pharmaceuticals Inc. - 10-Q Summary (Q2 2025)

Business Context and Reporting Period

This report covers the quarterly period ended June 30, 2025. Aurinia Pharmaceuticals Inc. is a biopharmaceutical company focused on autoimmune diseases, primarily commercializing LUPKYNIS (voclosporin) for lupus nephritis and developing aritinercept (AUR200). The company is incorporated in Alberta, Canada, and trades on the Nasdaq Global Market under the symbol AUPH.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Growth: Total revenue increased 22% year-over-year for the six months ended June 30, 2025, driven by a 23% increase in net product sales due to higher LUPKYNIS carton sales and market penetration.
• Profitability Turnaround: The company reported a net income of $44.9 million for the first six months of 2025, compared to a net loss of $10.0 million in the same period in 2024. Operating income improved from a loss of $14.8 million to a profit of $41.9 million.
• Expense Reduction: Selling, General, and Administrative (SG&A) expenses decreased significantly by $46.3 million year-over-year (YTD), primarily due to headcount reductions from 2024 restructuring and lower marketing costs. Restructuring expenses also dropped from $7.8 million to $1.6 million YTD.
• Share Repurchases: The company repurchased 11.2 million shares for $90.8 million in the first half of 2025, compared to 3.4 million shares for $18.6 million in the prior year period.

Outlook, Risks, and Unusual Items

• Guidance & Outlook: Management expects SG&A expenses to remain lower in 2025 as restructuring benefits are realized. R&D expenses are expected to increase due to development activities for aritinercept. The company plans to initiate clinical studies for aritinercept in the second half of 2025 following positive Phase 1 results.
• Unusual Items: "Other expense (income), net" increased to $13.7 million (YTD 2025) from a gain of $4.4 million (YTD 2024). This is primarily due to foreign exchange remeasurement losses on the Swiss Franc-denominated Monoplant finance lease liability and changes in fair value assumptions for deferred compensation.
• Risks & Contingencies:
  • Patent Litigation: The company received Paragraph IV notices from eight generic manufacturers (including Hikma, Teva, and Sandoz) seeking to launch generic LUPKYNIS prior to patent expiry in 2037. Aurinia has filed patent infringement lawsuits against all eight parties.
  • Regulatory/Trade: Risks associated with U.S. investigations into pharmaceutical imports and potential retaliatory tariffs from international partners (Otsuka Territories) could impact supply chains and revenue.
• Subsequent Event: On July 31, 2025, the Board approved an additional $150 million increase to the share repurchase program.

Investor Verification Checklist

• Patent Litigation Status: Monitor the progress of the eight patent infringement lawsuits filed in April and May 2025 against generic applicants.
• FX Exposure: Verify the impact of Swiss Franc fluctuations on the Monoplant lease liability and future earnings.
• Restructuring Completion: Confirm that the November 2024 restructuring costs are fully paid and that headcount reductions are sustaining the projected SG&A savings.
• Share Repurchase Activity: Track the execution of the expanded $300 million total repurchase authorization announced in July 2025.
• Aritinercept Pipeline: Watch for updates on the initiation of clinical studies for aritinercept in the second half of 2025.